DUBLIN–(BUSINESS WIRE)–The “Presbyopia – Market Insight, Epidemiology and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.
This ‘Presbyopia – China Market Insight, Epidemiology, and Market Forecast-2032’ report deliver an in-depth understanding of Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trend in China.
The Presbyopia market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted China Presbyopia market size from 2019 to 2032. The Report also covers current Presbyopia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
The goal of treatment is to compensate for the inability of your eyes to focus on nearby objects. Treatment includes wearing corrective eyeglasses (spectacle lenses) or contact lenses, undergoing refractive surgery, or getting lens implants for presbyopia. Most clinical management of presbyopia includes nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, or some other tempering agents.
The commonly used off-label ophthalmic drops have pilocarpine, carbachol, aceclidine, brimonidine, and nepafenac as their main ingredient. They target the ciliary muscles and change the pupil size and elasticity thereby improving the near vision. Recently the US FDA approved Vuity developed by AbbVie for the treatment of presbyopia in adults.
However, there are currently no approved presbyopia-correcting therapeutics in China. There is a high unmet need for new therapies to treat presbyopia. To fill the unmet gap, several companies are conducting clinical trials to investigate new treatment options, and some interesting therapies are heading down the pipeline.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Presbyopia, total diagnosed cases of Presbyopia, total age-specific cases of Presbyopia, gender-specific cases of Presbyopia, and severity-specific cases of Presbyopia scenario of Presbyopia in China from 2019 to 2032.
- According to the publisher analysis, China accounted for 329,861,640 Presbyopia prevalent cases in the year 2021. These cases are expected to grow by the year 2032.
- China accounted for 282,919,791 Presbyopia diagnosed cases in the year 2021, which are expected to rise by the year 2032.
- In China, the total age-specific cases of Presbyopia were 77,066,373, 107,043,777, 67,159,677, and 31,649,963 cases for the age group 40-49 years, 50-59 years, 60-69 years, and ?70 years, respectively in the year 2021. These cases are expected to rise significantly by 2032.
- In China, the total gender-specific cases of Presbyopia were 124,155,342 and 158,764,448 cases for males and females, respectively in the year 2021.
- In China, the total severity-specific cases of Presbyopia were 84,875,937 and 198,043,854 cases for mild cases and moderate to severe cases, respectively in the year 2021.
Presbyopia Emerging Drugs
ARVN003 (Microline): Arctic Vision and Eyenovia
ARVN003 (known as MicroLine in the US) of Eyenovia is a patented micro-dosed pilocarpine formulation distributed through the Optejet dispenser of the Business. Pilocarpine works by creating a Pinhole effect, which is done by the constricting of the pupil of the eye, similar to a pinhole camera, and brings near and medium-distance objects into focus. The drug is presently being evaluated in phase III (VISION -2) to determine the safety and efficacy of 2% pilocarpine ophthalmic spray in adults with presbyopia.
In 2020 Arctic Vision received an exclusive license from Eyenovia for the development and commercialization of ARVN003 (MicroLine) in Greater China and South Korea, and in 2021 it received IND clearance from the Center for Drug Evaluation, China National Medical Products Administration (CDE, NMPA) for a Phase III study of ARVN003 (pilocarpine microdose ophthalmic solution) for the treatment of presbyopia. It is the first clinical trial to be approved in China for presbyopia treatment.
Brimochol PF and Carbachol PF: Zhaoke Ophthalmology Limited and Visus Therapeutics
Brimochol PF (VT-101) and Carbachol PF of Visus Therapeutics are pupil-modulating eye drops that are meant to be once-daily, preservative-free therapies for the correction of presbyopia-related loss of near vision. Brimochol PF is carbachol (a cholinergic agent) and brimonidine tartrate fixed-dose combination (an alpha-2 agonist). Carbachol PF is a patented carbachol monotherapy formulation that is free of preservatives. Both investigational therapies reduce the pupil, creating a “pinhole effect” that allows only centrally directed light rays to enter the eye, intensifying near and intermediate image treatment. The drug is presently being evaluated in phase III (BRIO-I and BRIO-II) to determine the safety and efficacy of Brimochol PF and Carbachol PF for the treatment of presbyopia.
In May 2022, Visus Therapeutics and Zhaoke Ophthalmology signed an exclusive licensing agreement for the development and commercialization of Brimochol PF and Carbachol PF in Greater China, South Korea, and select Southeast Asian territories, with Zhaoke Ophthalmology responsible for clinical development, regulatory approval, and product commercialization in the said territories.
LNZ100 (aceclidine) & LNZ101 (aceclidine + brimonidine): Ji Xing Pharmaceuticals and LENZ Therapeutics
LNZ100, a 1.75% aceclidine formulation being developed by LENZ Therapeutics, is the first and only aceclidine-based eye drop to provide a seamless vision for the vast majority of all presbyopes. While LNZ101 is a combination of 1.75% aceclidine with brimonidine for the treatment of presbyopia with the potential for increased duration of treatment and an added advantage of eye whitening. Both formulations use a proprietary, preservative-free vehicle matrix to maximize comfort, efficiency, and bioavailability. LENZ therapeutics plans to start its pivotal Phase III trial in the second half of 2022.
LENZ Therapeutics and Ji Xing Pharmaceuticals signed an exclusive license agreement in April 2022 to develop and market LNZ100 and LNZ101 for the treatment of presbyopia in Greater China.
List of products to be continued in the report.
Presbyopia Market Outlook
Despite decades of research, treatment options for Presbyopia are restricted. The goal of treatment is to compensate for the inability of the eyes to focus on nearby objects.
Current treatment options are typically device or surgery-based, such as reading glasses, contact lenses, corneal procedures, and multifocal intraocular lens implantation. Presbyopia cannot be cured, but properly prescribed glasses or contact lenses can make seeing up close much more comfortable. Though reading glasses are the most common solution for near-vision correction, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons.
There are currently no approved presbyopia-correcting therapeutics in China. Vuity (AGN-190584), developed by Allergan (which was acquired by AbbVie), is a miotic 1.25% pilocarpine hydrochloride ophthalmic solution, is the first and only FDA-approved eye drop to treat presbyopia, an eye condition that affects nearly half of the US adult population. The approval was based on results from two pivotal Phase III studies, GEMINI 1 and GEMINI 2, which demonstrated the drugs’ effectiveness in improving near and intermediate vision without impacting distance vision using the eye’s own ability to reduce the pupil size. The company might also plan to launch this drug in China for the treatment of presbyopia.
There is a high unmet need for new therapies to treat presbyopia. To fill the unmet gap, several companies are conducting clinical trials to investigate new treatment options, and some interesting therapies are heading down the pipeline. Key players such as Arctic Vision and Eyenovia (ARVN003/MicroLine), Visus therapeutics and Zhaoke Ophthalmology (Brimochol PF and Carbachol PF), Lenz Therapeutics and JiXing (LNZ100 and LNZ101), Ocuphire Pharma (Nyxol), Novartis (UNR844), Allergan (acquired by AbbVie) (AGN-241622), Orasis Pharmaceuticals (CSF-1/PresbiDrops), and others are investigating their candidates for the management of presbyopia in China.
According to the publisher, the treatment space for Presbyopia will experience a significant impact in the coming years due to the launch of new therapies and a rise in healthcare spending across the world.
- The market size of Presbyopia in China was USD 14,375 million in 2021, which is further expected to increase by 2032.
- The expected launch of new potential therapies may increase market size in the coming years, assisted by an increase in the prevalent population of Presbyopia.
- Upcoming therapies such as ARVN003, Brimochol PF, and others have the potential to create a significant positive shift in the Presbyopia market size in near future.
Presbyopia Report Key Strengths
- 11-Years Forecast
- China Coverage
- Presbyopia Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Presbyopia Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
- Arctic Vision and Eyenovia
- Visus therapeutics and Zhaoke Ophthalmology
- Lenz Therapeutics and JiXing
- Orasis Pharmaceuticals
- Ocuphire Pharma
- Glaukos Corporation
For more information about this report visit https://www.researchandmarkets.com/r/x5az48
The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.